TARRYTOWN, N.Y. and PARIS, Jan. 7, 2019 /PRNewswire/ — Companies select two clinical-stage bispecific antibodies for ongoing collaboration Regeneron retains full rights to all its other investigational immuno-oncology programs; Sanofi able to independently pursue own immuno-oncology…

Source: https://www.prnewswire.com:443/news-releases/regeneron-and-sanofi-restructure-immuno-oncology-collaboration-for-discovery-and-development-programs-300773538.html

This entry was posted on Monday, January 7th, 2019 at 2:30 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.